| DIRECT COMPETITOR COMPARISON | |
| ARRY | ARQL | THRX | VRTX | Industry | | Market Cap: | 89.74M | 154.17M | 834.57M | 7.07B | 78.16M | | Employees: | 348 | 107 | 191 | 1,310 | 474 | | Qtrly Rev Growth (yoy): | 37.30% | 141.60% | -8.10% | -21.00% | 13.50% | | Revenue (ttm): | 27.12M | 23.28M | 26.50M | 100.81M | 141.20M | | Gross Margin (ttm): | 24.83% | -96.61% | -154.41% | N/A | 47.15% | | EBITDA (ttm): | -87.72M | -34.24M | -69.40M | -565.14M | 8.84M | | Oper Margins (ttm): | -346.62% | -154.58% | -281.68% | -590.65% | 7.12% | | Net Income (ttm): | -118.93M | -35.90M | -79.02M | -625.87M | N/A | | EPS (ttm): | -2.479 | -0.814 | -1.263 | -3.815 | 0.03 | | P/E (ttm): | N/A | N/A | N/A | N/A | 22.87 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.44 | | P/S (ttm): | 3.47 | 6.83 | 31.49 | 70.78 | 1.78 |
|
| ARQL = ArQule Inc. | | THRX = Theravance Inc. | | VRTX = Vertex Pharmaceuticals Incorporated | | Industry = Medical Laboratories & Research | |
| NEWS ON DIRECT COMPETITORS | |
| • | THRX | | UPDATE - FDA denies approval for Theravance's pneumonia drug
Fri, Nov 27 -
at Reuters | | • | THRX | | Theravance says FDA delays new Vitabiv decision
Fri, Nov 27 -
AP | | • | THRX | | THERAVANCE INC Files SEC form 8-K, Other Events
Fri, Nov 27 -
EDGAR Online | | • | THRX | | Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Fri, Nov 27 -
Marketwire | | • | THRX | | Theravance, Inc.: Wait to Buy on Dip
Thu, Nov 26 -
at Seeking Alpha | | • | VRTX | | The Technical Indicator: U.S. markets hesitate at the 2009 peak
Tue, Nov 24 -
at MarketWatch | | • | VRTX | | Become a Recessionista? Not in This Stock Market
Mon, Nov 23 -
TradingMarkets.com | | • | VRTX | | [$$] The Hunt for Tech Stocks, Broadly Defined
Sat, Nov 21 -
at Barrons.com | | • | VRTX | | Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Fri, Nov 20 -
Business Wire | | • | ARQL | | ArQule, Inc.: Warming Up or Cooling Off?
Thu, Nov 19 -
at Motley Fool | | • | VRTX | | UPDATE - InterMune to modify hep C study to drop one dosage
Tue, Nov 17 -
at Reuters | | • | ARQL | | Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference
Mon, Nov 16 -
Business Wire | | • | THRX | | Unique Strategy Generates Big Returns for Baupost
Fri, Nov 13 -
Indie Research | | • | ARQL | | ARQULE INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | ARQL | | ArQule, Inc. to Present at Lazard Capital Markets Sixth Annual Healthcare Conference on November 17, 2009
Tue, Nov 10 -
Business Wire | | • | ARQL | | New Star Analyst Rankings for ArQule, Inc.
Sun, Nov 8 -
StarMine | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
